VBIV - VBI Vaccines Company Buyout Price

Brandmark of vbivaccines.com (VBIV)

VBI Vaccines Inc. (VBIV) faces challenges in developing antiviral agents due to geopolitical tensions that are obstructing component logistics and the execution of tests. To compete with market leaders, VBI Vaccines Inc. (VBIV) employs flexible pricing for its vaccines by offering discounts to insurers. The asset's price trajectory, where the Enterprise Value stands at , confirms the business's resilience to crises driven by stable demand for preventive medicine.

VBIV (VBI Vaccines, Inc.) Total Company Value history from 07/04/2022 to 10/31/2026

VBI Vaccines (VBIV) - metric breakdowns and financial figures

- stock price and consensus target price:
Price Chart VBI Vaccines, Inc.|VBIV - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization VBI Vaccines|VBIV - Real Price to Acquire Entire Company
- balance sheet equity data:
Net Assets per Single Share VBI Vaccines|VBIV - Company Book Value|Market Capitalization to Net Assets vbivaccines.com|VBIV - Company Total Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio VBI Vaccines Inc.|VBIV - Long-Term Debt to Capital|Short-Term Debt to Capital VBI Vaccines, Inc.|VBIV - Company Debts|Debt to Net Assets Ratio VBI Vaccines|VBIV - Company Long-Term Debt|Company Current Liabilities VBI Vaccines|Quick Ratio vbivaccines.com
- net income and valuation multiples indicators:
VBIV - Net Income
Analysis of all company metrics:VBI Vaccines Inc.
Brand item of VBI Vaccines

Enterprise Value represents the total buyout price of a business, combining market capitalization and net debt. By analyzing fluctuations in enterprise value, an investor assesses the real financial burden of VBI Vaccines Inc. (VBIV), including capital-intensive expenditures for ESG compliance regarding safe waste disposal and the implementation of energy-saving technologies in biotechnological production.

Competitors of VBI Vaccines Inc. (VBIV)

Gilead - Total Company Value|Cidara Therapeutics Inc - Enterprise Value|Company Buyout Price Novavax Pharma NVAX|CVAC (CureVac N.V.) - Real Price to Acquire Entire Company|VALN (valneva.com) - Total Company Value|Total Company Value Vir Biotechnology|SIGA Technologies Inc - Full Business Value|Enterprise Value EBS|AVIR (Atea Corp) - Value Adjusted for Debt and Cash|Enterprise Value IVVD (Invivyd)|Enterprise Value enanta.com ENTA|INO - Total Company Value|Value Adjusted for Debt and Cash HLVX (HilleVax Inc)|Kalaris Therapeutics, Inc. (KLRS) - Total Company Value|Real Price to Acquire Entire Company Dyadic International, Inc.|NNVC (NanoViricides Inc.) - Enterprise Value|Enterprise Value talphera.com|Real Price to Acquire Entire Company COCP (Cocrystal Pharma)|TRAW (trawspharma.com) - Value Adjusted for Debt and Cash|Dogwood Therapeutics - Real Price to Acquire Entire Company|Qualigen Corp - Total Company Value|AlloVir Bio - Enterprise Value|Company Buyout Price Virios Therapeutics VIRI|vaxart.com (VXRT) - Total Company Value